The Evolving Role of Enzalutamide on the Treatment of Prostate Cancer

References

• Ryan CJ , SmithMR, De BonoJSet al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med.368(2), 138–148 (2013).
   PubMed Web of Science ®Google Scholar
• Beer TM , ArmstrongAJ, RathkopfDEet al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med.371(5), 424–433 (2014).
   PubMed Web of Science ®Google Scholar
• De Bono JS , LogothetisCJ, MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364(21), 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Scher HI , FizaziK, SaadFet al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med.367(13), 1187–1197 (2012).
   PubMed Web of Science ®Google Scholar
• Tran C , OukS, CleggNJet al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science324(5928), 787–790 (2009).
   PubMed Web of Science ®Google Scholar
• Guerrero J , AlfaroIE, GomezF, ProtterAA, BernalesS. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate73(12), 1291–1305 (2013).
   PubMed Web of Science ®Google Scholar
• Scher HI , BeerTM, HiganoCSet al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase-2 study. Lancet375(9724), 1437–1446 (2010).
   PubMed Web of Science ®Google Scholar
• Higano CS , BeerTM, TaplinMEet al. Long-term safety and antitumor activity in the Phase 1–2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur. Urol.68(5), 795–801 (2015).
   PubMed Web of Science ®Google Scholar
• Sternberg CN , De BonoJS, ChiKNet al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the Phase III AFFIRM trial. Ann. Oncol.25(2), 429–434 (2014).
   PubMed Web of Science ®Google Scholar
• Saad F , De BonoJ, ShoreNet al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur. Urol.67(2), 223–230 (2015).
   PubMed Web of Science ®Google Scholar
• Penson D AA , ConcepcionRet al. A multicenter Phase 2 study of enzalutamide (ENZA) versus bicalutamide (BIC) in men with nonmetastatic (M0) or metastatic (M1) castration-resistant prostate cancer (CRPC): the STRIVE Trial. Presented at: AUA Annual Meeting. New Orleans, LA, USA, 15–19 May 2015 ( Abstract PII-LBA10).
   Google Scholar
• Shore Nd HA , Villersaet al. TERRAIN trial: prostate-specific antigen kinetics and quality of life results of enzalutamide versus bicalutamide in metastatic castration-resistant prostate cancer. Presented at: AUA Annual Meeting. New Orleans, LA, USA, 15–19 May 2015 ( Abstract PII-LBA4).
   Google Scholar
• Sweeney CJ , ChenYH, CarducciMet al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med.373(8), 737–746 (2015).
   PubMed Web of Science ®Google Scholar
• Gravis G , FizaziK, JolyFet al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, Phase 3 trial. Lancet Oncol.14(2), 149–158 (2013).
   PubMed Web of Science ®Google Scholar
• James MRS Nicholas David, Malcolm David Mason, et al. Stampede Investigators. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J. Clin. Oncol.33(Suppl.), Abstract 5001 (2015).
   Google Scholar
• Tombal B , BorreM, RathenborgPet al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, Phase 2 study. Lancet Oncol.15(6), 592–600 (2014).
   PubMed Web of Science ®Google Scholar
• Tombal B , BorreM, RathenborgPet al. Long-term efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 1- and 2-year open-label follow-up results. Eur. Urol.68(5), 787–794 (2015).
   PubMed Web of Science ®Google Scholar
• Liu C , LouW, ZhuYet al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res.75(7), 1413–1422 (2015).
   PubMed Web of Science ®Google Scholar
• Sharifi N . Steroid receptors aplenty in prostate cancer. N. Engl. J. Med.370(10), 970–971 (2014).
   PubMed Web of Science ®Google Scholar
• Claessens F , HelsenC, PrekovicSet al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat. Rev. Urol.11(12), 712–716 (2014).
   PubMed Web of Science ®Google Scholar
• Antonarakis ES , LuC, WangHet al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med.371(11), 1028–1038 (2014).
   PubMed Web of Science ®Google Scholar
• Balbas MD , EvansMJ, HosfieldDJet al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife2, e00499 (2013).
   PubMed Web of Science ®Google Scholar
• Korpal M , KornJM, GaoXet al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov.3(9), 1030–1043 (2013).
   PubMed Web of Science ®Google Scholar
• Azad AA , VolikSV, WyattAWet al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer. Res.21(10), 2315–2324 (2015).
   PubMed Web of Science ®Google Scholar
• Arora VK , SchenkeinE, MuraliRet al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell155(6), 1309–1322 (2013).
   PubMed Web of Science ®Google Scholar
• Noonan KL , NorthS, BittingRL, ArmstrongAJ, EllardSL, ChiKN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann. Oncol.24(7), 1802–1807 (2013).
   PubMed Web of Science ®Google Scholar
• Bianchini D , LorenteD, Rodriguez-VidaAet al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur. J. Cancer50(1), 78–84 (2014).
   PubMed Web of Science ®Google Scholar
• Cheng HH , GulatiR, AzadAet al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis.18(2), 122–127 (2015).
   PubMed Web of Science ®Google Scholar